Australian company Immutep (ASX:IMM) has announced positive data from a trial of its LAG-3 immunotherapy, eftilagimod alpha, in combination with MSD's KEYTRUDA (pembrolizumab). …
Positive efficacy result for Immutep’s 'efti' in combination with MSD's KEYTRUDA
October 23, 2023 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 26 October
October 26, 2026 - - Podcast -
Documents reveal net PBS spending set to remain on life support to the end of decade
October 26, 2026 - - Latest News -
Health's multi-million dollar rebuild of cost-recovery fees is happening out of view
October 26, 2026 - - Latest News -
There is an urgent need to reconsider the question of PBS sustainability
October 26, 2026 - - Latest News -
UTI and contraception care comes to local pharmacies from February
October 26, 2026 - - Latest News -
PBS share of health spending on track to halve as Canberra prepares to negotiate with industry
October 26, 2026 - - Latest News -
Australia leads the way as Moderna and MSD take personalised cancer vaccine into lung cancer
October 24, 2026 - - Latest News